Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.
- Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.
- Dr. Cohen, an independent investor and former biopharma chief executive officer, is a co-founder of Exelixis and has served as a member of the companys Board of Directors since November 1995.
- For more information about Exelixis, please visit www.exelixis.com , follow @ ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
- Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.